Overview
ICCC market data
Price History
ICCC price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.12 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.55 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.52 – $12.10 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $100.4M · P/B 2.06 · P/S 3.35.
Company News
ImmuCell Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 14, 2026, 3:51 PM
8-K filing — IMMUCELL CORP /DE/ (ICCC)SEC EDGAR · Aug 13, 2026, 8:07 PM
ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoYBenzinga · Aug 13, 2026, 8:06 PM
ImmuCell Q2 Total Product Sales Rises 12%Benzinga · Jul 9, 2026, 8:10 PM
ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoYBenzinga · May 14, 2026, 8:08 PM